Gastrointestinal non-systemic virus disinfection as a new paradigm and a new modality for successful prevention, prophylaxis, and therapy to SARS-Cov-2 and Covid-19
Created at: 2021.11.09
Gastrointestinal non-systemic virus disinfection as a new paradigm and a new modality for successful prevention, prophylaxis, and therapy to SARS-Cov-2 and Covid-19
Executive summary:
1. Vaccination is the key element to overcome SARS-CoV-2 pandemic, however vaccination alone, results no full control over pandemic. New waves, with new infections, re-infections, post-covid virus latency happen. Therefore, new paradigm, new treatment modalities shall be developed, deployed.
2. Vaccination have mostly systemic effect, therefore virus may also be present in the GI tract of asymptomatic carriers and of Covid-19 patients, too.
3. Successful repurposing of drugs with well-established use (WEU) is the quickest, safest route of development of medicines with new indication.
4. R&D professionals of PannonPharma have identified an strong antiviral agent against SARS-CoV-2, which may apply in GI tracts due to its non-systemic effect.
5. This repurposed (WEU) drug has a double action, in its GI tract disinfection mechanism, and it is code named, as CovGiDi (Corona virus disinfection).
6. It is a safe and efficient, non-systemic, mainly gastrointestinal antibiotic agent, acting against coronaviruses, including all their recent, present and future mutants, as well.
7. Prevention / prophylaxis with CovGIDI ought be done already at early gastric symptoms of SARS-CoV-2 infection (discomfort, pain, nausea, vomiting, diarrhoea etc.).
8. Prompt action in SARS-CoV-2 pandemic might be possible with Temporary Emergency Marketing Authorization.
9. We are looking for the opportunities to cooperate with pharmaceutical industry, universities, governmental control/ regulatory authorities.
Beyond the vaccination
Vaccination is the key element to overcome SARS-CoV-2 pandemic, however, vaccination alone, results no full control over pandemic. New waves, new infections, re-infections happen, therefore new treatment modalities shall also be developed, deployed.
Where do the SARS-CoV-2 viruses infect? Covid-19 and the gastrointestinal system
The increase of SARS-CoV-2 in excreta is generally known as indicator in pandemic: it predicts the soon appearance of the mass infection in communities. No doubt, virus is present in the GI tract of Covid-19 patients earlier than the very first clinical symptoms of infection appear.
Primary SARS-CoV-2 infection targets the upper respiratory tract in majority of cases. But, the more and more frequently appearing secondary infection indicated by gastrointestinal discomfort, pain, and other symptoms, may lead, to sever or critical clinical condition, in 60-70% of hospitalized patients, estimated in the clinical literature.
Delta / Lambda mutants infect faster and more intensely than the former ones. They attack not only in the upper respiratory tract, but invade more violently and latently in the GI tract of Covid-19 patients. In the human body, the most exposed surface to the SARS-CoV-2 infection is the GI tract, because 80% of the cell surface receptors (ACE2) - capable of binding to the virus - are localized to the intestines. The cells on the intestinal mucosa are attacked and destroyed by coronavirus constantly, which may lead to a very dangerous clinical state. Moreover, even after the clinical course of an acute infection, SARS-CoV-2 mutants may be infectious for weeks or months, if they persist in the gut. It is more than likely that the persistent virus may also play a role in the development of postcovid symptoms and / or in the recurrence of COVID-19 infection, too.
Complex problems require a simple solution based on a new paradigm
Obviously, successful repurposing of drugs with well-established use (WEU) is the quickest, safest route of development of medicines, which target an unmet medical need, generated by Covid-19. R&D engineers of PannonPharma have identified an antiviral agent against SARS-CoV-2, which may apply in GI tracts due to its non-systemic effect.
Repurposed, well-established use medicine, with strong SARS-CoV-2 antiviral non-systemic effect is ready for emergency use at COVID-19 patients, by viral disinfection of their gastrointestinal tract
This repurposed (WEU) drug has a double disinfection mechanism which lies in blocking the virus entry into the host cell, and denaturize the virus, itself. It seems to be as a safe and efficient, mainly gastrointestinal, non systemic antibiotic agent, acting against all kinds of enveloped, peplon type coronaviruses, including all their recent, present and forthcoming mutants, as well. To support clinical observations and results, inhibitory and antiviral (killing) activity of the WEU coded as CovGIDI (i.e. coronavirus-gastrointestinal disinfection) drug was tested and confirmed against SARS-CoV-2 by applying international standard cytopathic virus assays.
Prevention with CovGIDI is possible in case of early gastric symptoms of SARS-CoV-2 infection
1. CovGIDI is proven to be antiviral in action against enveloped (peplon coated) viruses, just like SARS-CoV-2 is, therefore the GI tract of COVID-19 patients might be successfully disinfected, even for majority of severely ill cases, too cases.
2. CovGIDI acts in the GI system. As intestines perform the most active and extensive immune activities, the disinfection of the guts significantly reduces the burden of the immune system, too. The overload of immune-capacity of the COVID-19 patients eases, therefore the infection of other organs might also be eliminated and the patients can recover completely.
3. The incidence of recurrent (re-infected) cases and/or the occurrence of post-covid symptoms will be reduced among COVID-19 patients, discharged from hospitals.
4. Vaccinated patients with low level of neutralizing antibodies can also be better protected in case of infection/reinfection. This WEU drug also kills new virus mutants and by stopping their replication and proliferation, the mutation and reinfection rate can also be reduced.
5. By its well-known WEU therapeutic characteristics, the development of some other common opportunistic infectious species can be inhibited in the intestines of COVID-19 patients.
6. This "ideal" antibiotic drug is not challenging the clinical condition of patients. In its mode of action, it is non-systemic by character, topically active, because by administration only the oral route and the GI lumen are exposed.
7. No serious adverse reaction, side effect is known, or published in clinical literature
8. In its general use for decades, this antibiotic is not showing any sign of resistance, none is known, published. Antibiotic resistance mught be hardly developing, due to the damage in the structure of SARS-CoV-2 envelope, caused by CovGIDI.
Prompt action against SARS-CoV-2 pandemic is possible
Hungarian / USA / international patents are submitted as indication extension of WEU drug and new drug formulation for the treatment of COVID-19 and similar diseases. Temporary Emergency Authorization can be given for WEU preventiv use of CovGIDI.
For cooperation possibilities please feel free to open any communication channel.
